Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20505796 | 0.86 | CCKBR (0.38) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL23758472 | 0.85 | CCKBR (0.37) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL13142140 | 0.83 | CCKBR (0.36) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL20329573 | 0.83 | BCHE (0.47) | CCKBRBCHE | |
| SCHEMBL24202026 | 0.82 | CCKBR (0.38) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL16684897 | 0.82 | CCKBR (0.39) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL12013752 | 0.79 | CCKBR (0.42) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL1118519 | 0.79 | CCKBR (0.42) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL12141050 | 0.79 | CCKBR (0.42) | CCKBRBCHEHRH2OPRM1HTR2B | |
| SCHEMBL8261364 | 0.76 | HTR5A (0.41) | CCKBRBCHEHRH2OPRM1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | BRITISH COLUMBIA CANCER AGENCY BRANCH | 2021-01-05 | — | — | US | disclosed |
| US-20190256549-A1 | PANAXDIOL-TYPE GINSENOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ARMY MEDICAL UNIVERSITY (CN) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256549-A1 | PANAXDIOL-TYPE GINSENOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | LDLR, NR1H2, TNF | CCKBR 1737/4885BCHE 2598/4885HRH2 2487/4885 |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | KLK3, FOLH1, FOLR1 | CCKBR 585/4885BCHE 2283/4885HRH2 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.